Ayala Pharmaceuticals, Inc. has heralded data from a Phase II/III trial on its investigational drug, AL102, for desmoid tumors, although investors seem concerned that the Israel-headquartered biotech has much to do to compete with rival SpringWorks Therapeutics Inc.'s nirogacestat.
The company unveiled updated interim results at the European Society for Medical Oncology (ESMO) congress in Paris from part A of the ongoing RINGSIDE pivotal trial evaluating AL102, an oral gamma-secretase inhibitor for desmoid tumors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?